What do systematic reviews say?

Low‐level laser therapy vs Low-level laser therapy (LLLT) + calcium hydroxide

Low-level laser therapy (LLLT) showed no clear difference in radiological failure compared with low-level laser therapy (LLLT) + calcium hydroxide; GRADE not reported.

• Pulp treatment for extensive decay in primary teeth 2018 · Cochrane All outcomes

  12 months
  RR 1.00 [0.24, 4.18]
  1 study · 30 participants
  GRADE not reported

Low‐intensity pulsed ultrasound vs control

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 393 participants
  Very low

Low‐intensity pulsed ultrasound vs control

The review found no eligible studies for this question.

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low‐intensity pulsed ultrasound vs control

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 370 participants
  Low

Low‐intensity pulsed ultrasound vs control

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 887 participants
  Very low

Low‐intensity pulsed ultrasound vs control

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 148 participants
  Very low

Low‐intensity pulsed ultrasound vs control

Low‐intensity pulsed ultrasound showed no clear difference in delayed or non‐union (medium term) compared with control (moderate certainty).

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  RR 1.25 [0.5, 3.09]
  7 studies · 746 participants
  Moderate

Low‐intensity pulsed ultrasound vs control

It is very uncertain whether low‐intensity pulsed ultrasound changes adverse events Reported as skin irritation compared with control (very low certainty).

• Ultrasound and shockwave therapy for acute fractures in adults 2023 · Cochrane Headline outcomes only
  RR 0.94 [0.06, 14.65]
  1 study · 101 participants
  Very low

Laminar air flow with HEPA filter vs Without laminar flow or filter

It is very uncertain whether laminar air flow with HEPA filter changes reduction in level of contamination in aerosols (CFU per cubic… compared with without laminar flow or filter (very low certainty).

• Interventions to reduce contaminated aerosols produced during dental procedures for preventing infectious diseases 2020 · Cochrane All outcomes
  MD -319.14 [-385.60, -252.68]
  1 study · 50 participants
  Very low

Laminar air flow with HEPA filter vs Without laminar flow or filter

It is very uncertain whether laminar air flow with HEPA filter changes reduction in level of contamination in aerosols (CFU per cubic… compared with without laminar flow or filter (very low certainty).

• Interventions to reduce contaminated aerosols produced during dental procedures for preventing infectious diseases 2020 · Cochrane All outcomes
  MD -483.56 [-550.02, -417.10]
  1 study · 50 participants
  Very low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.8 [0.6, 1.08]
  2 studies · 947 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.62 [0.4, 0.97]
  4 studies · 279 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.78 [0.25, 2.46]
  3 studies · 162 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.76 [0.52, 1.12]
  3 studies · 238 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in disease‐free survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.84 [0.65, 1.09]
  1 study · 828 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in pathological complete response (no invasive cancer in breast or… compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.15 [0.96, 1.38]
  4 studies · 1280 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.25 [0.86, 1.82]
  1 study · 280 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.95 [0.55, 1.65]
  2 studies · 1108 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose reduction) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.81 [0.59, 1.11]
  1 study · 280 participants
  Moderate